European Psychiatry - Volume 33 - March 2016

248 / 812

S244 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
Pain and treatment options
EW374
The fibromyalgia patients would
present higher levels of magnification
that controls pain: A pilot study
K. Cabas-Hoyos ∗, J.L. Mu˜noz-Salgado , I. Cadavid-Perez ,
L. De Hoyos , G. Gonzalez-Gamero , L. Luna-Martinez ,
I. Perez-Solano , L. Quintero-Soto , F. Roman
1 Grupo CAVIDA, Facultad de Psicología, Universidad Pontificia
Bolivariana, sede Montería, Cra 6 # 97 A 99, Montería, Colombia
2 CENEM, Centro de Neurociencias Monteria, Neuropsiquiatria,
Montería, Colombia
3 Universidad Maimónides, Doctorado en Psicologia con orientación
en Neurociencia Cognitiva, Buenos Aires, Argentina
∗ Corresponding author.
Catastrophism is a variable of great importance in the study of pain.
Catastrophism refers to a negative and exaggerated compared to
the experience of pain, both real and anticipated mental percep-
tion (Sullivan, Bishop and Pivik, 1995; Sullivan et al., 2001). The
current study to compare the levels of catastrophism in patients
with and without fibromialgia. This study is cross-cutting and com-
parative. Twenty participants (M: 47.20; SD: 12.11) distributed as
the following way:
– group 1: patients with fibromyalgia previously diagnosed
through the American College of Rheumatology criteria (n = 10);
– group 2: Clinical depression, defined according to the DSM-5
(n = 5);
– group 3: healthy patients (n = 5) paired by age with the group of
Fibromyalgia.
The PCS, a self-administered, was used to measure Catastrophism.
Responses were summed to yield three different subscales:
Rumination, Magnification and Helplessness. This instrument is
validated in both experimental and clinical population (Van
Damme, Crombez, Bijttebier, Gouber and Van Houdenhove, 2002;
Edwards et al., 2006). A comparison among the three groups was
established using one-way factor ANOVA. The results point out
that patients with fibromyalgia have higher levels of magnification
controls with depression and healthy group ( P< 0.05). In contrast,
although the average level of Catastrophism total presented a
greater tendency in fibromyalgia patients no statistically signifi-
cant differences were found. This is discussed in relation to the
literature, a higher level of magnification to explain pain and main-
taining the chronicity of the disease. It is important to consider the
component catastrophism to have amultidimensional viewof pain.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW375
Women that present fibromyalgia
have higher levels in all scales of
catastrophism
K. Cabas-Hoyos
Universidad Pontificia Bolivariana, Grupo CAVIDA, Montería,
Colombia
Fibromyalgia patients value their pain as modern high and they
perceive it more as a threat than as a challenge (Ayan, 2011).
There is a relative consensus related to catastrophic thoughts that
seems to play an important role in the maintenance of chronic pain
(Esteve, Ramírez and López, 2001). The objective of the present
study was to explore the level of catastrophism in women with
and without fibromyalgia. Adult women (n = 39) with an average
of 47 years old (TD: 12.14) and more than 12 years schooling,
paired with healthy controls (n = 39) with similar characteristics.
Patients with fibromyalgia were previously diagnosed according
to ACR (American College of Rheumatology). This was a cross-
sectional study, comparative and quantitative cut. An ANOVA was
used to compare both groups. The level of catastrophismwas mea-
sured through the Pain Catastrophizing Scale (Sullivan, Bishop and
Pivick, 1995). Scale composed of 13 questions and three subscales:
rumination, magnification and hopelessness. This instrument has
been tested in both clinical and non-clinical populations (Osman
et al., 2000; Sullivan et al., 1995). Rumination, magnification and
hopelessness were trend significantly higher in the women group
with Fibromyalgia. [Rumination: F (1.36) = 6.22; P = 0.00]; [Magni-
fication: F (1.36) = 17.66; P = 0.00]; [Hopelessness: F (1.36) = 6.53;
P = 0.00]. These results allowed that the total catastrophism level
was higher in the women groupwith Fibromyalgia and that the sta-
tistical significance level was reached [F (1.36) = 9.89; P = 0.00). This
type of studies will allow to study the pain as a multidimensional
entity comprised of physical, cognitive and affective aspects.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW376
Chronic non-malignant pain (CNMP)
and substance use disorders
L. Herrera Duran ∗, I. Falgas , B. Cook , N. Noyola , M. Toro ,
M. Alegria
1 Massachusetts General Hospital, Disparities Research Unit, Boston,
USA
2 Vall d’hebrón University Hospital/Universitat Autonoma de
Barcelona, Department of Psychiatry and Forensic Medicine,
Barcelona, Spain
3 Cambridge Health Alliance and Harvard Medical School, Health
Equity Research Lab, Boston, USA
∗ Corresponding author.
Introduction Chronic non-malignant pain (CNMP) is defined as
pain lasting a minimum of three months. In general, chronic pain
affects 20% adult worldwide population. Moreover, pain is more
common in patients with depression, anxiety, and substance-use
disorders and with low socioeconomic status. We aimed to better
understand the influence of pain on substance use and treatment
use patterns of individuals who experienced clinically recognized
pain and have substance use disorder.
Methods Patients with pain disturbances were identified in Elec-
tronic Health Records (EHR) through ICD-9 code 338*, medical
written diagnoses, or diagnoses of fibromyalgia. A patient was
considered to have a substance use disorder if he received treat-
ment for illicit drug or alcohol abuse or dependence. We combined
2010–2012 (EHR) data from primary care and specialty mental
health setting in a Boston healthcare system (n = 131,966 person-
years) and a specialty mental health care setting in Madrid, Spain
(n = 43,309 person-years).
Results We identified that 35.3% of individualswith clinically rec-
ognized pain also report substance use disorder, compared to only
10.6% of individuals without clinically recognized pain (P < 0.01).
Those with co-morbid pain and substance use disorder were signif-
icantly more likely than their specialty care counterparts without
co-morbid pain and substance disorders to be seen in the emer-
gency room (56.5% vs. 36.6%, respectively, P < 0.01).
Conclusion The findings suggest that CNMP is associated with an
increase risk of substance abuse disorder.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.